• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection

National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection

by Ron Shinkman | Sep 26, 2025 | Clinical Diagnostics Insider, Emerging Tests-dtet, FDA-dtet

The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: BD Receives FDA Approval for Veritor, a Pandemic Staple

FDA Watch: BD Receives FDA Approval for Veritor, a Pandemic Staple

by Ron Shinkman | Sep 19, 2025 | Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

The assay was widely used during the early months of COVID-19 and was a significant source of revenue growth for a time

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: Agency Launches Database of Complete Response Letters Sent to Drug Manufacturers About Initial Rejections

FDA Watch: Agency Launches Database of Complete Response Letters Sent to Drug Manufacturers About Initial Rejections

by Ron Shinkman | Aug 27, 2025 | Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

The early focus is on drug applications, but it could spread to the laboratory test approval process as well

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Will Not Appeal Ruling Against LDT Regulation, Giving a Big Victory to Labs

FDA Will Not Appeal Ruling Against LDT Regulation, Giving a Big Victory to Labs

by Ron Shinkman | Jul 11, 2025 | Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor, Labs in Court-nir, LDTs-lir

The legal strategy of the ACLA—and some political luck—prevailed in the lawsuit against LDT oversight

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Expanding Test Menus: A Compliance Roadmap for FDA-Regulated Labs

Expanding Test Menus: A Compliance Roadmap for FDA-Regulated Labs

by Tara Cepull, MA | Jul 11, 2025 | Compliance-lca, Compliance-nir, Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

Two OIG advisory opinions guide laboratories that want to work with pharma or medical device companies on expanded testing

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries
Next Entries »

Log In

Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2026 G2Intelligence.com